ONO-2020
- Generic Name
- ONO-2020
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Phase 2
Recruiting
- Conditions
- Agitation Associated With Alzheimer's Disease Dementia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06803823
- Locations
- 🇯🇵
Hatano Kousei Hospital, Kanagawa, Japan
🇯🇵Rainbow & Sea Hospital, Saga, Japan
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT06881836
- Locations
- 🇺🇸
Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies CRU, Decatur, Georgia, United States
🇺🇸ActivMed Research, Methuen, Massachusetts, United States
🇯🇵Inage Neurology and Memory Clinic, Chiba, Japan
A Phase 1 Study of ONO-2020 in Healthy Participants
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT05507515
- Locations
- 🇺🇸
Altasciences, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath